Sign in

William Dubin

Research Analyst at Leerink

William Dubin's questions to KalVista Pharmaceuticals (KALV) leadership

William Dubin's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

William Dubin sought more detail on the patient profile beyond prior therapy, specifically asking about any meaningful patterns observed in attack rate severity, attack frequency, and typical attack rates before initiating ECTERLEET treatment.

Answer

Nicole Sweeny, Chief Commercial Officer, indicated that while market research suggested early adopters would be high-burden patients, adoption has been seen across a wide array of patient types and burden of disease. She noted that the utilization of prophylaxis among ECTERLEET patients aligns with overall market share for prophylaxis, demonstrating broad population use regardless of disease burden or prior/current treatment.

Ask Fintool Equity Research AI

William Dubin's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

William Dubin sought more information on the patient profile beyond prior therapy, specifically asking about meaningful patterns in attack rate severity, attack frequency, and typical attack rates before initiating EKTERLY treatment.

Answer

Nicole Sweeny, Chief Commercial Officer, stated that while market research indicated high-burden patients would be early adopters, adoption has been observed across a wide array of patient types and burden of disease. She added that current prophylaxis utilization among EKTERLY patients aligns with overall market share, indicating broad use regardless of prior on-demand or current prophylactic treatment.

Ask Fintool Equity Research AI